Screening programmes for chlamydial infection: when will we ever learn?

Nicola Low

BMJ 2007;334:725-728
doi:10.1136/bmj.39154.378079.BE

Updated information and services can be found at:
http://bmj.com/cgi/content/full/334/7596/725

These include:

Data supplement

“References”
http://bmj.com/cgi/content/full/334/7596/725/DC1

References

This article cites 12 articles, 4 of which can be accessed free at:
http://bmj.com/cgi/content/full/334/7596/725#BIBL

1 online articles that cite this article can be accessed at:
http://bmj.com/cgi/content/full/334/7596/725#otherarticles

Rapid responses

5 rapid responses have been posted to this article, which you can access for free at:
http://bmj.com/cgi/content/full/334/7596/725#responses

You can respond to this article at:
http://bmj.com/cgi/eletter-submit/334/7596/725

Email alerting service

Receive free email alerts when new articles cite this article - sign up in the box at the top left of the article

Topic collections

Articles on similar topics can be found in the following collections

- Diagnostics tests (384 articles)
- Other Public Health (2630 articles)
- Sexually Transmitted Infections - other than HIV / AIDS (1304 articles)
- Screening (694 articles)
- UK government (1194 articles)
- Governments - non UK (653 articles)

Notes

To order reprints follow the “Request Permissions” link in the navigation box

To subscribe to BMJ go to:
http://resources.bmj.com/bmj/subscribers
Screening programmes for chlamydial infection: when will we ever learn?

With more countries recommending screening programmes for chlamydial infection, Nicola Low argues that such programmes are not underpinned by sound evidence.

The notion that a programme of widespread screening in Sweden controlled transmission of chlamydial infection and reduced morbidity of the female reproductive tract is commonly cited as fact. Unfortunately, this assertion and similar claims about screening in the United States and Canada are not supported by rigorous research or practice. Here, I will show how misinterpretation of what comprises a screening programme led to uncritical acceptance of the effectiveness of chlamydia screening, and the funding of a National Chlamydia Screening Programme in England, before the benefits and harms were evaluated.

Screening for chlamydial infection in Sweden

Swedish researchers were key players in demonstrating the importance of sexually transmitted chlamydial infection in the 1970s and 1980s. They were instrumental in developing diagnostic tests and defining the role of C. trachomatis in pelvic inflammatory disease and infertility. The first documented “program to identify asymptomatics” started in 1982 and tested women under 30 years seeking contraception, abortion, or antenatal care and male partners of infected women. In 1988, a change in the Swedish infectious diseases law required doctors to provide free testing, treatment, and partner notification for anyone with suspected chlamydia and to report cases. There were educational campaigns, and young people’s clinics were established to make testing easily available.

Rates of chlamydia and its complications decreased up to the mid-1990s, at the same time as widespread testing was introduced (fig 1). Financing services, strong infrastructure, open attitudes to sexual health, and a small population were suggested to contribute to this success. Studies such as these have now been cited as evidence of success of organised chlamydia screening programmes up to 80 times in Web of Science indexed journals and in official reports.

In fact, the fall in rates of chlamydia infection in Sweden coincided with the national campaign to prevent HIV (fig 1). Desire to believe in chlamydia screening seems to have displaced alternative explanations, such as changing sexual behaviour, even though parallel decreases in sexually transmitted infections in countries with no efforts to control chlamydia were attributed to HIV prevention campaigns. Reports of the effectiveness of screening in Sweden persist, despite increasing rates of diagnosed chlamydia since 1995 (fig 1).

Nicola Low, reader in epidemiology and public health, Department of Social and Preventive Medicine, University of Bern, Bern, CH-3012, Switzerland

Correspondence to: low@ispun.unibe.ch

SUMMARY POINTS

Lack of an agreed concise definition of a screening programme has contributed to beliefs about the effectiveness of opportunistic screening for chlamydial infection

Opportunistic screening as currently implemented in the National Chlamydia Screening Programme in England has not been evaluated in randomised controlled trials

Criteria for assessing the appropriateness for introducing a screening programme have not been rigorously applied to chlamydial infection

Countries implementing or contemplating national chlamydia screening should conduct research to determine if such screening programmes do more good than harm at reasonable cost

Fig 1 | Rate of laboratory diagnosed chlamydial infection in Sweden 1985 to 2005

Screening for chlamydia in the US

In the US, opportunistic screening was also credited with decreases in rates of chlamydial infection. The Centers for Disease Control and Prevention have supported screening programmes since 1988. A federally funded national Infertility Prevention Program that provides chlamydia screening for women on low incomes attending certain healthcare settings was established by 1995. The most recent report showed that chlamydia positivity in women aged 15-24 years screened in family planning clinics decreased in two of 10 regions from 2003 to 2004, increased in six, and remained the same in two.

The National Chlamydia Screening Programme in England

A programme offering opportunistic chlamydia screening (box 1) to all sexually active women and men under 25 years attending a variety of healthcare settings in England is due to be implemented by 2008. One-off screening opportunities in commercial pharmacies, universities, colleges, and other venues are also encouraged. The programme aims to, “control genital chlamydial infection through the early detection and treatment of asymptomatic infections and prevention of sequelae and onward transmission.”

In two pilot sites, all general practitioners took part, were paid for each patient enrolled, and generated the highest proportion of tests and cases, achieving an effective screening rate (box 1) of 50%. In the programme itself, participation of general practitioners...
is optional and largely unreimlayered. In 2005-6, the effective screening rate was less than 5% in more than half of programme areas. Performance indicators do not measure key outcomes of repeat screening, prevalence of chlamydial infection, or morbidity.

**What is a screening programme?**

A “screening programme” has no agreed concise definition, although “screening” (box 1) is well defined. Any health service activities that facilitate early disease detection could therefore be called a programme, if certain criteria are fulfilled. I suggest that it should be defined as a continuing organised service that ensures that screening is delivered at sufficiently regular intervals to a high enough proportion of the target population to achieve defined levels of benefit at the population level, while minimising harm (box 1).

In fact, no national chlamydia screening programme exists in Sweden, and “national strategies for the entire area of sexual health and sexuality are presently lacking.” Locally funded activities that promote testing for chlamydial infection for case finding, underpinned by legislation, were widely described and interpreted as screening programmes. Reliance on the obligations of individual doctors without national coordination, objectives, or outcome standards does not fulfil the suggested definition and is unlikely to achieve the aims of screening.

**Appropriateness of a chlamydia screening programme**

Chlamydia would seem to be an ideal candidate for screening. *Chlamydia trachomatis* is a common, curable, easily diagnosed, sexually transmitted infection that usually causes no symptoms. It can, however, cause devastating complications, including infertility, ectopic pregnancy, neonatal infection, and facilitation of HIV transmission.

Agreed standards should be applied to all diseases for which screening is in place or is being considered. Screening programmes approved by the National Screening Committee require registers that allow proactive invitations (box 1) to be sent to people in the target population to ensure regular uptake. The alternative is opportunistic screening, which reaches people attending health or other services (box 1). A health professional is responsible for offering the test at regular intervals. Cervical cancer screening in the United Kingdom was initially opportunistic, but screening was poorly targeted and consistent reductions in mortality only occurred after a proactive programme increased regular coverage.

Opportunistic screening is widely assumed to be the only acceptable model of service delivery for chlamydia. In England, postal invitations to young people who were not yet sexually active were deemed inefficient and the coverage of opportunistic screening stated to be adequate before alternatives had been investigated. The assumption about coverage was based on high acceptance (box 1) once chlamydia screening had been offered. However, not everyone uses the services that provide testing and not everyone who uses those services is offered a test. Subsequent research has shown that effective screening rates (box 1) are 30-40% for both proactive and opportunistic approaches, and costs per screening invitation are similar.

Gray has suggested another important difference between chlamydial infection and chronic diseases: that a person’s risk of acquiring an infection depends on its prevalence in the population. A chlamydia screening programme must therefore control...
transmission through both regular screening and partner notification to reduce morbidity. Thus, the model for chlamydia screening might differ from that for a non-communicable disease, but standards for the organisation and appropriateness of screening should be the same. Key criteria of the National Screening Committee, outlined below, have not been stringently applied to chlamydia.18

Natural history should be adequately understood Increasing evidence shows that the rate of progression of endocervical chlamydia to pelvic inflammatory disease is lower than previously thought.19 Population based studies consistently estimate lower incidence rates of pelvic inflammatory disease than clinic based studies.19 Infections detected by screening asymptomatic people might therefore have a better prognosis than symptomatic infections, because of differences in the burden of the organism. Descriptions of chlamydial infection and its consequences,5 and models of the impact of screening,18 however, nearly always cite the higher estimates.

Evidence from high quality randomised controlled trials The Department of Health funded pilot studies of opportunistic chlamydia screening,24 even though no randomised controlled trial had shown that this intervention reduced long term morbidity.1 The National Screening Committee accepted that, “In Scandinavia, screening for chlamydia has been found to reduce the risk of infertility and ectopic pregnancy,”92 on the basis of only uncontrolled ecological studies. A systematic review, commissioned after the National Chlamydia Screening Programme was introduced, has confirmed that no randomised controlled trial has evaluated opportunistic chlamydia screening as it is currently practised.15 Evidence from trials of proactive screening cannot be extrapolated to opportunistic screening and is limited by methodological biases that overestimate the benefits.15 No trial evidence about the effects of more than one round of screening for either approach is available.

Value for money Most studies cited as showing that chlamydia screening is cost effective do not satisfy accepted quality criteria for economic evaluations.18 The need for dynamic mathematical modelling has been largely ignored, in contrast with work on other infections.18 Furthermore, most studies make two assumptions that overestimate the cost effectiveness of chlamydia screening—that the incidence of pelvic inflammatory disease and regular screening rates are higher than are seen in practice.1 Under realistic assumptions, introducing a chlamydia screening programme is likely to be an expensive intervention.18

Lessons to be learnt Belief in the success of opportunistic screening persists,3 6 despite an absence of evidence of effectiveness17 and increasing rates of chlamydia in countries

Box 2 | Research needed to establish benefits and harms of chlamydia screening programmes

<table>
<thead>
<tr>
<th>Validity of screening tests</th>
</tr>
</thead>
<tbody>
<tr>
<td>Systematic review of diagnostic studies of nucleic acid amplification tests to determine if higher observed yields of <em>Chlamydia trachomatis</em> in vulval or vaginal specimens than in urine specimens is clinically important</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Epidemiology and natural history of the condition</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cohort studies to track progression of lower genital tract <em>C trachomatis</em> infection (detected with nucleic acid amplification) to pelvic inflammatory disease and other reproductive tract morbidity. Stored repeated endocervical specimens (such as those from human papillomavirus vaccine trials), with linkage to medical records, could be used</td>
</tr>
<tr>
<td>Cohort studies to estimate the incidence of neonatal complications after perinatal maternal chlamydial infections detected with nucleic acid amplification tests</td>
</tr>
<tr>
<td>Prospective studies of the associations between quantitative measures of chlamydial organism load, symptomatic and asymptomatic lower and upper genital tract disease, and transmission of infection</td>
</tr>
<tr>
<td>Prospective studies to define appropriate screening intervals more accurately</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Effectiveness of screening for reducing morbidity</th>
</tr>
</thead>
<tbody>
<tr>
<td>Randomised controlled trials to examine the effectiveness of opportunistic and proactive chlamydia screening, including more than one round of screening and measuring uptake of initial and repeat invitations, and biological outcomes</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Value for money</th>
</tr>
</thead>
<tbody>
<tr>
<td>Cost effectiveness analysis using economic and epidemiological data collected in randomised controlled trials and dynamic mathematical models to examine the impact of interventions on transmission of chlamydia and incidence of complications</td>
</tr>
<tr>
<td>Prospective studies to determine utility values for quality adjusted life years with pelvic inflammatory disease, ectopic pregnancy, tubal infertility, and epididymo-orchitis</td>
</tr>
</tbody>
</table>

that are assumed to have such programmes.5 6 4 Increased testing with highly sensitive tests explains only part of the observed rise. In Sweden, rates of chlamydial infection in 15-19 year olds began to increase before nucleic acid amplification tests were available, and rates were also increasing in some laboratories before they changed diagnostic methods.8 Reasons that have been suggested to explain the resurgence of chlamydia include inadequate partner notification,10 and a loss of immunity after widespread early treatment.4 The possibility that the opportunistic screening approach has not achieved regular screening has not been widely discussed.9 Unsubstantiated belief also seems to have allowed the requirements of the National Screening Committee and the experience of other UK screening programmes to be over-ridden. Uncertainty about the status of chlamydia screening is, however, emerging. National Screening Committee policy is that screening should not be offered to pregnant women10 owing to insufficient evidence of effectiveness, whereas the National Chlamydia Screening Programme recommends screening in antenatal clinics.2 Countries currently considering introducing screening policies or programmes include France, Romania and Slovenia,7 Ireland,11 the Netherlands,12 and Australia.13 Policy makers and researchers in these countries need to learn from the past and move forward by generating the evidence required (Box 2) to determine whether this intervention does more good than harm at reasonable cost.
Contributors: NL is an epidemiologist and accredited physician in genitourinary medicine and public health with a research interest in screening programmes for sexually transmitted infections. This article uses information that emerged from a longstanding collaboration on Chlamydia in Uppsala, Sweden with Bjorn Hermann and Matthias Egger, and is based on plenary talks at the Australasian Sexual Health Conference 2006 and the 22nd IUSTI-Europe Conference on Sexually Transmitted Infections 2006. Discussions and research collaborations with Judith Stephenson, University College London, and Jackie Cassell, Brighton and Sussex Medical School, also informed the present discussion.

Funding: NL is employed by the University of Bern, which received funding from the UK National Institute for Health and Clinical Excellence (NICE). Part of the research referred to in this article was commissioned by NICE to inform the development of its forthcoming guidance on the prevention of sexually transmitted infections, and the full report is available online [www.nice.org.uk/page.do?o=37177]. This article does not constitute NICE guidance. The Chlamydia Screening Studies (CaSSS) project was funded by the NHS Health Technology Assessment programme (project number 97/32/31).

Competing interests: None declared.

Provenance and peer review: Not commissioned; externally peer reviewed.

Analysis articles: advice to authors

These articles aim to stimulate discussion, raise debate, and air controversies. They can cover any aspects of medicine and health that are relevant to an international general medical audience, including sociological and ethical aspects of medicine, polemical pieces, and educational articles. These articles (whether single pieces or short series of articles) are mostly unsolicited.

They should include:

• 1500-1800 words set out under informative subheadings. Please include a 100-150 word introduction spelling out what the paper is about and emphasising its importance

• No more than 20 references in Vancouver style, presenting the evidence on which the key statements in the paper are made

• Up to three tables, boxes, or illustrations (clinical photographs, imaging, line drawings, or figures—we welcome colour). We may be able to publish some additional boxes or figures on bmj.com only

• A summary box with up to five short, single sentences highlighting the main points

• A statement of data sources and selection criteria: as well as the standard statements of funding, competing interests, and contributorship

At the end of every accepted analysis article the BMJ will add a statement explaining the article’s provenance (such as “Non-commissioned, externally peer reviewed”).

We may ask authors submitting unsolicited articles, particularly those covering topics with related commercial interests, these questions before proceeding:

• Has anyone (particularly a company or public relations agency) prompted or paid you to write this article?

• Would/did a professional writer contribute to the article, and to what extent?

• Would the BMJ article be similar to articles submitted or published elsewhere?

Even if the answers to all of these questions were “yes,” we wouldn’t necessarily reject the proposal or article. We appreciate that companies can commission some excellent evidence based work and that professional writers can present that evidence in a particularly readable and clear way that benefits readers and learners. We would, however, expect such companies’ and writers’ contributions to be mentioned in the article. And we would want to know that the BMJ article did not overlap by more than 15% with any similar publications or submissions written by the same authors elsewhere.